相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2016
招募中
2
100.0%
暂无批准数据
- GV20 Therapeutics will present updated Phase 1 data on GV20-0251, the first AI-designed antibody targeting the novel immune checkpoint IGSF8, at ASCO 2025. - The presentation will showcase clinical and translational findings from patients with advanced solid tumors resistant to anti-PD(L)1 therapies, with a focus on melanoma patients showing primary resistance. - GV20-0251 represents a significant advancement in AI-driven drug discovery, having progressed from target identification to IND filing in just three years with promising early efficacy data.
- GV20 Therapeutics has formed a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation to develop first-in-class antibody-drug conjugates targeting novel tumor antigens. - The partnership will utilize GV20's proprietary STEAD AI platform for antibody discovery combined with MTPC's expertise in linker-payload technology to advance innovative cancer therapeutics. - Under the agreement, GV20 will receive an upfront payment plus milestone payments, while MTPC gains exclusive negotiation rights for licensing the antibodies during the collaboration period.
- GV20 Therapeutics presented Phase 1 data for GV20-0251, marking the first clinical results for an AI-designed antibody targeting an AI-predicted immune checkpoint IGSF8. - The study enrolled 38 heavily pre-treated patients and demonstrated favorable safety with no dose-limiting toxicities across all dose levels from 0.5 to 20 mg/kg. - Two confirmed partial responses were observed in 12 evaluable metastatic cutaneous melanoma patients, with 14 of 29 patients showing stable disease including tumor shrinkage. - The drug showed dose-proportional pharmacokinetics with a 25.6-day half-life and full target occupancy on circulating T cells at doses ≥3 mg/kg.
